Quick Ratio (Acid-Test): 0.89
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 0.89 is 58% above its 5-year average of 0.57, near the high end of its 5-year range (0.00–0.95).
As of Monday, June 29, 2026. 1.96% above its 12-month average of 0.88.
GEHC Quick Ratio
Reported quarterly quick ratio; no daily interpolation.
GEHC Average Quick Ratio (Acid-Test) Chart
GEHC Current vs Average Quick Ratio (Acid-Test) Chart
GEHC Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
0.89
QUICK RATIO (ACID-TEST) AVG TTM
0.88
QUICK RATIO (ACID-TEST) AVG 3Y
0.85
QUICK RATIO (ACID-TEST) AVG 5Y
0.57
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.96%
CURRENT VS 3Y AVG
+4.78%
CURRENT VS 5Y AVG
+58.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GEHC Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.91B | 0.89 | 0.88 | 0.85 | 0.57 |
| ResMed Inc. (RMD)vs › | $29.05B | 2.53 | 2.11 | 1.94 | 1.80 |
| Zoetis Inc. (ZTS)vs › | $31.88B | 1.94 | 1.51 | 1.66 | 1.96 |
| Biogen Inc. (BIIB)vs › | $31.89B | 2.03 | 1.46 | 1.69 | 1.64 |
| IQVIA Holdings Inc. (IQV)vs › | $31.90B | 0.75 | 0.79 | 0.83 | 0.90 |
| Veeva Systems Inc. (VEEV)vs › | $27.84B | 4.89 | 4.70 | 4.39 | 4.08 |
| Centene Corp. (CNC)vs › | $32.44B | 1.68 | 1.40 | 1.24 | 1.19 |
| DexCom, Inc. (DXCM)vs › | $27.07B | 1.59 | 1.44 | 1.80 | 2.83 |
| Medline Inc. (MDLN)vs › | $32.87B | 2.37 | 1.97 | 2.09 | 2.09 |
| Moderna, Inc. (MRNA)vs › | $26.69B | 3.22 | 3.42 | 3.19 | 2.63 |
Liquidity Comparison
Quick Ratio
0.89
Excludes inventory
Current Ratio
1.18
Includes inventory
Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for GE HealthCare Technologies Inc. (GEHC)?
- The quick ratio (acid-test) for GEHC stock is 0.89.
- Is GE HealthCare Technologies Inc.'s quick ratio (acid-test) high or low?
- The quick ratio (acid-test) of 0.89 is 58% above its 5-year average of 0.57, near the high end of its 5-year range (0.00–0.95).
- What is the TTM average quick ratio (acid-test) for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average quick ratio (acid-test) for GEHC stock is 0.88.
- What is the 3Y average quick ratio (acid-test) for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average quick ratio (acid-test) for GEHC stock is 0.85.
- What is the 5Y average quick ratio (acid-test) for GE HealthCare Technologies Inc. (GEHC)?
- The 5Y average quick ratio (acid-test) for GEHC stock is 0.57.
GEHC Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-03-31 | 0.89 |
| 2025-12-31 | 0.93 |
| 2025-09-30 | 0.95 |
| 2025-06-30 | 0.89 |
| 2025-03-31 | 0.72 |
| 2024-12-31 | 0.79 |
| 2024-09-30 | 0.94 |
| 2024-06-30 | 0.77 |
| 2024-03-31 | 0.79 |
| 2023-12-31 | 0.78 |
| 2023-09-30 | 0.92 |
| 2023-06-30 | 0.87 |
| 2023-03-31 | 0.84 |
| 2022-12-31 | 0.79 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
Related Metrics
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini